Positions

Overview

  • After receiving a bachelor’s degree in pharmaceutical sciences in 1998, Dr. Nukaya earned a Ph.D. in 2004 from Hokkaido University Graduate School of Pharmaceutical Sciences in Japan. Dr. Nukaya joined the laboratory at McArdle Laboratory for Cancer Research at the University of Wisconsin at Madison under Professor Christopher Bradfield in 2004 to engage in postdoctoral research. Dr. Nukaya conducted signature research efforts on understanding the toxic effects of “dioxin,” an environmental toxin in the liver. From 2009, Dr. Nukaya has participated in basic and translational research focused on chemoprevention of intestinal bowel disease and colorectal cancer with Dr. Gregory Kennedy, Director of Gastrointestinal Surgery at University of Alabama at Birmingham. Dr. Nukaya’s research interest is in the characterization of Aryl Hydrocarbon Receptor (AHR) in liver and colorectal disease.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2017 The aryl hydrocarbon receptor as an antitumor target of synthetic curcuminoids in colorectal cancerJournal of Surgical Research.  213:16-24. 2017
    2016 The aryl hydrocarbon receptor is a repressor of inflammation-associated colorectal tumorigenesis in mouseAnnals of Surgery.  264:429-435. 2016
    2016 Indole-3-carbinol induces tumor cell death: Function follows formJournal of Surgical Research.  204:47-54. 2016
    2016 Aryl hydrocarbon receptor-dependent apoptotic cell death induced by the flavonoid chrysin in human colorectal cancer cellsCancer Letters.  370:91-99. 2016
    2014 Liver tumor promotion by 2,3,7,8-tetrachlorodibenzo-p-dioxin is dependent on the aryl hydrocarbon receptor and TNF/IL-1 receptorsToxicological Sciences.  140:135-143. 2014
    2012 SU5416, a VEGF Receptor Inhibitor and Ligand of the AHR, Represents a New Alternative for ImmunomodulationPLoS ONE.  7. 2012
    2012 Identification of the Ah-receptor structural determinants for ligand preferencesToxicological Sciences.  129:86-97. 2012
    2012 AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of NotchNature Immunology.  13:144-152. 2012
    2010 Aryl hydrocarbon receptor nuclear translocator in hepatocytes is required for aryl hydrocarbon receptor-mediated adaptive and toxic responses in liverToxicological Sciences.  118:554-563. 2010
    2010 The aryl hydrocarbon receptor-interacting protein (AIP) is required for dioxin-induced hepatotoxicity but not for the induction of the Cyp1a1 and Cyp1a2 genesJournal of Biological Chemistry.  285:35599-35605. 2010
    2009 The role of the dioxin-responsive element cluster between the Cyp1a1 and Cyp1a2 loci in aryl hydrocarbon receptor biologyProceedings of the National Academy of Sciences.  106:4923-4928. 2009
    2009 Conserved genomic structure of the Cyp1a1 and Cyp1a2 loci and their dioxin responsive elements clusterBiochemical Pharmacology.  77:654-659. 2009
    2007 Hepatic transcriptional networks induced by exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxinChemical Research in Toxicology.  20:1573-1581. 2007
    2005 CYP1A1-mediated mechanism for atherosclerosis induced by polycyclic aromatic hydrocarbonsBiochemical and Biophysical Research Communications.  337:708-712. 2005
    2005 A possible mechanism for atherosclerosis induced by polycyclic aromatic hydrocarbonsBiochemical and Biophysical Research Communications.  335:220-226. 2005
    2004 Aryl hydrocarbon receptor-mediated suppression of GH receptor and Janus kinase 2 expression in miceFEBS Letters.  558:96-100. 2004
    2001 Awl hydrocarbon receptor-mediated suppression of expression of the low-molecular-weight prekininogen gene in miceBiochemical and Biophysical Research Communications.  287:301-304. 2001

    Education And Training

  • Doctor of Science in Pharmaceutical Sciences, Hokkaido University 2004
  • Full Name

  • Manabu Nukaya